I was at the AGM and definitely no mention of CR. But it must be realised the CR was good way to bring in cornerstone investors and put a floor under the price. The investors would have done a ton of DD which should provide us with confidence this is the real deal. AGM discussion was clear that the pathway to FDA is low risk and revenue will quickly get to 10% market share. It’s not hard to see where the value is going.
LTP Price at posting:
98.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)